Lunai Bioworks Inc. Segments Disclosure

NOTE 14 — SEGMENT REPORTING

 

For the year ended June 30, 2025, the Company had three reportable segments. These segments have different strategic and economic goals and are managed separately because they require different technology and marketing strategies.

 

Reportable Segment		Description
RENB		Developing new immunotherapies to combat cancer
BioSymetrics		Integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine.
RENC		Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection

 

The Company’s chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly. During the year ended June 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision maker assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The accounting policies of each segment are the same as those described in the summary of significant accounting policies.

 

Schedule of segment operating loss and asset information
		Operating loss				Assets
United States (RENB)		$	15,530,056			$	1,907,647
United States (BioSymetrics)			237,880				6,109,643
Netherlands (RENC)			173,198,066				213,550
		$	188,966,002			$	8,230,840

 

The chief operating decision maker uses loss from operations to evaluate the performance of each segment’s assets in deciding how to allocate available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by benchmarking the Company’s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are used in assessing the performance of the segment.

 

Information regarding each reportable segment for the year ended June 30, 2025 is as follows:

 

Schedule of information regarding segment reporting
		RENB				BioSymetrics				RENC				Total
General and administrative		$	14,904,855			$	211,401			$	2,763,794			$	17,880,050
Research and development			502,896				26,029				8,503				537,428
Goodwill impairment			—				—				170,419,429				170,419,429
Depreciation and amortization			122,305				450				6,340				129,095
Segment operating loss		$	15,530,056			$	237,880			$	173,198,066				188,966,002

 

Geographic information:

 

RENB, BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively. The geographic information analyses the Company’s operations and assets based on the country in which each segment operates. In presenting this geographic information, segment operating results have been based on the geographic location in which the services were provided to the segment and segment assets were based on the geographic location of the assets.